Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

Monoclonal antibody (mAb) therapy has rapidly changed the field of cancer therapy. In 1997, the CD20-targeting mAb rituximab was the first mAb to be approved by the U.S. Food and Drug Administration (FDA) for treatment of cancer. Within two decades, dozens of mAbs entered the clinic for treatment of...

Full description

Bibliographic Details
Main Authors: Hilma J. van der Horst, Inger S. Nijhof, Tuna Mutis, Martine E. D. Chamuleau
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/12/10/3041